Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2005 Jun;12(6):449-58. Epub 2005 Apr 19.

PMID:
15864482
2.

Predictors of regional nodal disease in patients with thin melanomas.

Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2006 Apr;13(4):533-41. Epub 2006 Mar 7.

PMID:
16523360
3.

Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.

Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, Chang AE, Yahanda AM, Moon J, Johnson TM.

Ann Surg Oncol. 2004 Mar;11(3):247-58.

4.

Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.

Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA.

Cancer. 2006 Nov 15;107(10):2436-45.

5.

American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.

Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane JM 3rd.

Ann Surg Oncol. 2006 Feb;13(2):198-204. Epub 2006 Jan 19.

PMID:
16418885
6.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
7.

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.

Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2007 Jan 1;109(1):100-8.

8.

Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm).

Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW.

Ann Surg Oncol. 2004 Oct;11(10):900-6. Epub 2004 Sep 20.

PMID:
15383424
9.

Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Rousseau DL Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE.

Ann Surg Oncol. 2003 Jun;10(5):569-74.

PMID:
12794025
10.

Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.

Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM.

Arch Dermatol. 2005 Aug;141(8):1016-22.

PMID:
16103331
11.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
12.

Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.

Karakousis GC, Gimotty PA, Czerniecki BJ, Elder DE, Elenitsas R, Ming ME, Fraker DL, Guerry D, Spitz FR.

Ann Surg Oncol. 2007 May;14(5):1596-603. Epub 2007 Feb 7.

PMID:
17285396
13.

Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.

Sabel MS, Griffith K, Sondak VK, Lowe L, Schwartz JL, Cimmino VM, Chang AE, Rees RS, Bradford CR, Johnson TM.

J Am Coll Surg. 2005 Jul;201(1):37-47.

PMID:
15978442
14.

Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.

Wagner JD, Gordon MS, Chuang TY, Coleman JJ 3rd, Hayes JT, Jung SH, Love C.

Cancer. 2000 Jul 15;89(2):453-62.

PMID:
10918179
15.

Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.

Gannon CJ, Rousseau DL Jr, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE.

Cancer. 2006 Dec 1;107(11):2647-52.

16.

Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.

Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L.

J Dtsch Dermatol Ges. 2008 Mar;6(3):198-203. Epub 2007 Dec 17. English, German.

PMID:
18093216
17.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22.

PMID:
19553103
18.

Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.

Debarbieux S, Duru G, Dalle S, Béatrix O, Balme B, Thomas L.

Br J Dermatol. 2007 Jul;157(1):58-67. Epub 2007 May 14.

PMID:
17501957
19.

Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.

Rossi CR, De Salvo GL, Bonandini E, Mocellin S, Foletto M, Pasquali S, Pilati P, Lise M, Nitti D, Rizzo E, Montesco MC.

Ann Surg Oncol. 2008 Apr;15(4):1202-10. doi: 10.1245/s10434-007-9734-8. Erratum in: Ann Surg Oncol. 2008 May;15(5):1552.

PMID:
18165880
20.

Sentinel lymph node biopsy for melanoma: indications and rationale.

Phan GQ, Messina JL, Sondak VK, Zager JS.

Cancer Control. 2009 Jul;16(3):234-9. Review.

Supplemental Content

Support Center